For Healthcare Professionals
Pro feature
By - September 30, 2015
OnabotulinumtoxinA is an approved prophylactic treatment for chronic migraine. Given every 12 weeks, onabotulinumtoxinA is thought to reverse peripheral sensitization, thereby indirectly reducing central sensitization.1 Research suggests that abnormally excitable central and... READ MORE

By - May 31, 2014
Data suggest that migraine with aura is associated with a slightly increase in risk of stroke,1 however, studies examining the association between migraine and subclinical cerebrovascular disease are limited to populations of... READ MORE

Featured Poll
Featured poll

What percentage of your migraine patients have experienced previous head/neck injury?